It was reported that reducing MLK1 expression can suppress MEK-ERK proliferation signaling and inhibit proliferation in pancreatic cancer cells [7]; therefore, development of MLK1 inhibitors could be a therapeutic means to treat pancreatic cancer. This evidence concerns the gene MAP3K9 and familial pancreatic carcinoma.